2,2-dimethylbutyric acid

structure given in first source; plasma metabolite of simvastatin

Also Known As:

2,2-DMB; 2,2-dimethylbutanoic acid; HQK-1001; NSC 741804; NSC-741804; NSC741804; SDMB; ST-20 compound; sodium 2,2-dimethylbutyrate

Networked: 7 relevant articles (0 outcomes, 4 trials/studies)

1.	Sickle Cell Anemia (Hemoglobin S Disease) 11/01/2013 - "Future studies are warranted to evaluate the therapeutic potential of HQK-1001 in sickle cell disease. " 11/01/2012 - "These findings of favorable PK profiles, tolerability, early rises in HbF, and total Hgb indicate that trials of longer duration appear warranted to more definitively evaluate the therapeutic potential of HQK-1001 in sickle cell disease." 11/01/2012 - "A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease."
2.	Pain (Aches) 07/01/2014 - "The mean annualized rate of pain crises was 3.5 with HQK-1001 and 1.7 with placebo. " 07/01/2014 - "The study was terminated after a planned interim analysis showed no significant increase in fetal hemoglobin (Hb F) and a trend for more pain crises in the HQK-1001 group. " 01/01/2023 - "Adverse effects reported for HQK-1001 were nausea, vomiting, dizziness and suprapubic pain. "
3.	Thalassemia 03/20/2014 - "A phase 2 trial of HQK-1001 in HbE-β thalassemia demonstrates HbF induction and reduced anemia."
4.	Anemia 03/20/2014 - "A phase 2 trial of HQK-1001 in HbE-β thalassemia demonstrates HbF induction and reduced anemia."
5.	Vomiting 01/01/2023 - "Adverse effects reported for HQK-1001 were nausea, vomiting, dizziness and suprapubic pain. " 07/01/2014 - "The most common adverse events in the HQK-1001 group, usually graded as mild or moderate, consisted of nausea, headache, vomiting, abdominal pain, and fatigue. "

1.	Globins
2.	Fetal Hemoglobin (Hemoglobin F)